^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
i
Other names: H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
National Cancer Institute
Drug class:
Immunostimulant
Related drugs:
5ms
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=30, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension
|
PD-L1 (Programmed death ligand 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
over1year
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=30, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
almost2years
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2; Phase classification: P2 --> P1/2
Phase classification
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
|
Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
almost2years
Randomized Phase II Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2; N=30; Not yet recruiting; Sponsor:National Cancer Institute (NCI)
New P2 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
|
Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
Share via
